Advancing the RA Armamentarium with Emerging Therapies

Faculty

Daniel Aletaha, MD
Associate Professor, Division of Rheumatology
Medical University of Vienna
Vienna, Austria

Clifton O. Bingham, III, MD
Assistant Professor of Medicine
Division of Rheumatology, Department of Medicine
John Hopkins University
Baltimore, Maryland

Paul Emery, MD
Arthritis Research UK Professor of Rheumatology
Head of Section, Musculoskeletal Disease
Leeds Institute of Molecular Medicine, University of Leeds
President, European League Against Rheumatism
Leeds, UK

Josef S. Smolen, MD
Professor of Internal Medicine and Chairman
Department of Rheumatology, Vienna General Hospital
Medical University of Vienna
Vienna, Austria

Intended Learners

This activity is designed for rheumatologists and related healthcare professionals who treat patients with rheumatoid arthritis (RA).

Learning Objectives

After completing this activity, participants should be able to:

• Outline changes to RA disease classification and remission criteria to develop appropriate therapeutic strategies for the aggressive pursuit of remission and management of comorbidities
• Interpret emerging data on the controllable factors that impact patient adherence to therapy
• Describe current data regarding safety issues associated with biologic therapies, such as risks of serious infections and side effects
• Compare and contrast the safety, efficacy, and clinical profiles of newer and emerging options for RA management
• Overcome hesitation to switch biologic therapy in patients receiving an inadequate response

Activity Overview

This activity is hosted on the Medscape website. Upon clicking the “Take Course Now” button above, you will be redirected to the Medscape site where full activity details, including instructions for receiving credit and faculty disclosure information, are available.

Accreditation Statement

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grant Statement

Supported by an educational grant from MedImmune, LLC.

Copyright Statement

Copyright © 2011 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.